LAMIVUDINE SANDOZ 150 mg, film-coated tablet scored 60 tablets
Active ingredients: Lamivudine
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet scored60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LAMIVUDINE SANDOZ 150 mg, comprimé pelliculé sécable
- Pharmaceutical form
- comprimé pelliculé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium OPA : polyamide orienté PVC-Aluminium de 60 comprimé(s)
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 26 Dec 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62822230CIP72750142CIP133400927501425Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAMIVUDINEcomprimé | 150 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.